|Articles|January 28, 2009

Lucentis approved in Japan

Lucentis (ranibizumab; Novartis) has been approved for the treatment of wet age-related macular degeneration (AMD) in Japan, Novartis has announced.

The application for approval in Japan was supported by a clinical trial demonstrating the efficacy of the anti-vascular endothelial growth factor (anti-VEGF) therapy. The approval comes simultaneously with three other Novartis drug approvals in Japan: Tasigna, for cancer, Xolair for asthma and Co-Dio for high blood pressure.

Lucentis has been approved in Europe since February 2007.

Newsletter

Don’t miss out—get OT Europe updates delivered straight to your inbox.

Subscribe

Lucentis approved in Japan

Related Content

AI's reach in retinal disease: Lab bench to bedside to backpack

Visual training may ease neuroadaptation to presbyopia-correcting IOLs

When to retest for inherited retinal dystrophies

Secondary IOL fixation: When to choose Yamane vs Gore-Tex

Effect of a maternal high-fat diet on the peripheral retina in mice

Latest CME

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

MacTel Decoded: Rethinking Conventional Approaches With Novel Neuroprotective Strategies

Treatment Optimization in the Evolving Anti-VEGF Era

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(CME Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

(COPE Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

(CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

(COPE Track) Next-Generation Solutions for nAMD and DME: Bridging Evidence and Practice Gaps in Disease Management

(COPE Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

Trending on Eye Care Network - Ophthalmology Times

Retinal imaging as a window into atrial fibrillation

The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD

OCT-980 receives FDA orphan drug designation for retinitis pigmentosa

First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP

Think outside the cone: Applying the Gulani Keratoconus Classification